1. Абросимов В.Н., Аристархов В.Г., Бяловский Ю.Ю., Вейс И.Е. Клиническая патофизиология. СПб.: СпецЛит, 2012. 432 с.
2. Баркаган З.С., Момот А.П. Диагностика и контролируемая терапия нарушений гемостаза. М.: Ньюдиамед, 2008.
3. Гусев Е.Ю., Черешнев В.А. Системное воспаление: теоретические и методологические подходы к описанию модели общепатологического процесса. Ч. 1. Общая характеристика процесса // Патол. физиология и эксперим. терапия. 2012. (4). 3–14.
4. Демьянов А.В., Котов А.Ю., Симбирцев А.С. Диагностическая ценность исследования уровней цитокинов в клинической практике // Цитокины и воспаление. 2003. 2. (3). 20–35.
5. Долгов В.В., Свирин П.В. Лабораторная диагностика нарушений гемостаза. Тверь: Триада, 2005. 227 с.
6. Папаян Л.П., Князева Е.С. D-димер в клинической практике: Пособие для врачей. М.: Инсайт полиграфика, 2002. 20 с.
7. Петрищев Н.Н., Васина Л.В., Власов Т.Д. Типовые формы дисфункции эндотелия // Клин.-лаб. консилиум. 2007. (18). 31–36.
8. Петрищев Н.Н., Власов Т.Д. Физиология и патофизиология эндотелия // Дисфункция эндотелия. Причины, механизмы, фармакологическая коррекция / ред. Н.Н. Петрищев. СПб., 2003. 184 с.
9. Чернеховская Н.Е., Шишло В.К., Чомаева А.А., Кодина Т.В. Эндотелий кровеносных и лимфатических сосудов. М.: ВНИИ животноводства, 2010. 182 с.
10. Alves B.E., Montalvao S.A.L., Aranha F.J.P., Lorand-Metze I., de Souza C.A., Annichino-Bizzacchi J.M., de Paula E.V. Time-course of sFlt-1 and VEGF-A release in neutropenic patients with sepsis and septic shock: a prospective study // J. Transl. Med. 2011. 9. (1). 23.
11. Arazi H.C., Doiny D.G., Torcivia R.S., Grancelli H., Waldman S.V., Nojek C., Fornari M.C., Badimon J.J. Impaired anti-platelet effect of aspirin, inflammation and platelet turnover in cardiac surgery // Interact. Cardiovasc. Thorac. Surg. 2010. 10. (6). 863–867.
12. Boehme M.W., Deng Y., Raeth U., Bierhaus A., Ziegler R., Stremmel W., Nawroth P.P. Release of thrombomodulin from endothelial cells by concerted action of TNF-alpha and neutrophils: in vivo and in vitro studies // Immunology. 1996. 87. (1). 134–140.
13. Boneu B., Abbal M., Plante J., Bierme R. Factor-VIII complex and endothelial damage // Lancet. 1975. 305. (7922). 1430.
14. Boneu B., Bes G., Pelzer H., Sie P., Boccalon H. D-Dimers, thrombin antithrombin III complexes and prothrombin fragments 1+2: diagnostic value in clinically suspected deep vein thrombosis // Thromb. Haemost. 1991. 65. (1). 28–31.
15. Brown Z., Gerritsen M.E., Carley W.W., Strieter R.M., Kunkel S.L., Westwick J. Chemokine gene expression and secretion by cytokine-activated human microvascular endothelial cells. Differential regulation of monocyte chemoattractant protein-1 and interleukin-8 in response to interferon-gamma // Am. J. Pathol. 1994. 145. (4). 913–921.
16. Cedervall J., Dimberg A., Olsson A.K. Tumor-induced local and systemic impact on blood vessel function // Mediators Inflamm. 2015. 2015. 1–8.
17. Cines D.B., Pollak E.S., Buck C.A., Loscalzo J., Zimmerman G.A., McEver R.P., Pober J.S., Wick T.M., Konkle B.A., Schwartz B.S., Barnathan E.S., McCrae K.R., Hug B.A., Schmidt A.M., Stern D.M. Endothelial cells in physiology and in the pathophysiology of vascular disorders // Blood. 1998. 91. (10). 3527–3561.
18. Cohen T., Nahari D., Cerem L.W., Neufeld G., Levi B.-Z. Interleukin 6 Induces the Expression of Vascular Endothelial Growth Factor // J. Biol. Chem. 1996. 271. (2). 736–741.
19. Dharmasaroja P., Dharmasaroja P.A., Sobhon P. Increased plasma soluble thrombomodulin levels in cardioembolic stroke // Clin. Appl. Thromb. Hemost. 2012. 18. (3). 289–293.
20. Dirkx A.E.M., oude Egbrink M.G.A., Wagstaff J., Griffioen A.W. Monocyte/macrophage infiltration in tumors: modulators of angiogenesis // J. Leukocyte Biol. 2006. 80. (6). 1183–1196.
21. Dormond O., Bezzi M., Mariotti A., Ruegg C. Prostaglandin E2 promotes integrin αVβ3-dependent endothelial cell adhesion, Rac-activation, and spreading through cAMP/PKA-dependent signaling // J. Biol. Chem. 2002. 277. (48). 45838–45846.
22. Duvoix A., Dickens J., Haq I., Mannino D., Miller B., Tal-Singer R., Lomas D.A. Blood fibrinogen as a biomarker of chronic obstructive pulmonary disease // Thorax. 2013. 68. (7). 670–676.
23. Emilie D., Wijdenes J., Gisselbrecht C., Jarrousse B., Billaud E., Blay J.Y., Gabarre J., Gaillard J.P., Brochier J., Raphael M. Administration of an anti-interleukin-6 monoclonal antibody to patients with acquired immunodeficiency syndrome and lymphoma: effect on lymphoma growth and on B clinical symptoms // Blood. 1994. 84. (8). 2472–2479.
24. Erdman L.K., Dhabangi A., Musoke C., Conroy A.L., Hawkes M., Higgins S., Rajwans N., Wolofsky K.T., Streiner D.L., Liles W.C., Cserti-Gazdewich C.M., Kain K.C. Combinations of host biomarkers predict mortality among Ugandan children with severe malaria: A retrospective case-control study // PLoS One. 2011. 6. (2). e17440.
25. Ferrara N. Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: Therapeutic implications // Semin. Oncol. 2002. 29. (6). 10–14.
26. Ferrara N., Davis-Smyth T. The biology of vascular endothelial growth factor // Endocr. Rev. 1997. 18. (1). 4–25.
27. Ferrara N., Keyt B. Vascular endothelial growth factor: Basic biology and clinical implications // EXS. 1997. 79. 209–232.
28. Fischer C., Jonckx B., Mazzone M., Zacchigna S., Loges S., Pattarini L., Chorianopoulos E., Liesenborghs L., Koch M., de Mol M., Autiero M., Wyns S., Plaisance S., Moons L., van Rooijen N., Giacca M., Stassen J.-M., Dewerchin M., Collen D., Carmeliet P. Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels // Cell. 2007. 131. (3). 463–475.
29. Folkman J. Angiogenesis // Annu. Rev. Med. 2006. 57. (1). 1–18.
30. Foss H.-d., Araujo I., Demel G., Klotzbach H., Hummel M., Stein H. Expression of vascular endothelial growth factor in lymphomas and Castleman’s disease // J. Pathol. 1997. 183. (1). 44–50.
31. Gabay C., Kushner I. Acute-phase proteins and other systemic responses to inflammation // N. Engl. J. Med. 1999. 340. (6). 448–454.
32. Gerber H.-P., Ferrara N. The role of VEGF in normal and neoplastic hematopoiesis // J. Mol. Med. (Berl). 2002. 81. (1). 20–31.
33. Hwa C., Aird W.C. The history of the capillary wall: doctors, discoveries, and debates // Am. J. Physiol. Heart Circ. Physiol. 2007. 293. (5). H2667–H2679.
34. Kadowaki I., Ichinohasama R., Harigae H., Ishizawa K., Okitsu Y., Kameoka J., Sasaki T. Accelerated lymphangiogenesis in malignant lymphoma: possible role of VEGF-A and VEGF-C // Br. J. Haematol. 2005. 130. (6). 869–877.
35. Kato H., Kinoshita T., Suzuki S., Nagasaka T., Hatano S., Murate T., Saito H., Hotta T. Production and effects of interleukin-6 and other cytokines in patients with non-Hodgkin’s lymphoma // Leuk. Lymphoma. 1998. 29. (1-2). 71–79.
36. Klein B., Wijdenes J., Zhang X.G., Jourdan M., Boiron J.M., Brochier J., Liautard J., Merlin M., Clement C., Morel-Fournier B. Murine anti-interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia // Blood. 1991. 78. (5). 1198–1204.
37. Kokame K., Zheng X., Sadler J.E. Activation of thrombin-activable fibrinolysis inhibitor requires epidermal growth factor-like domain 3 of thrombomodulin and is inhibited competitively by protein C // J. Biol. Chem. 1998. 273. (20). 12135–12139.
38. Krishnaswamy G., Kelley J., Yerra L., Smith J.K., Chi D.S. Human endothelium as a source of multifunctional cytokines: molecular regulation and possible role in human disease // J. Interferon Cytokine Res. 1999. 19. (2). 91–104.
39. Kuby J. Role of cytokines in the inflammatory response. Immunology, 2nd edition / Ed. J. Kuby. N.Y.: W.H. Freeman and Company, 1994. 313–315.
40. Lin S.-M., Wang Y.-M., Lin H.-C., Lee K.-Y., Huang C.-D., Liu C.-Y., Wang C.-H., Kuo H.-P. Serum thrombomodulin level relates to the clinical course of disseminated intravascular coagulation, multiorgan dysfunction syndrome, and mortality in patients with sepsis // Crit. Care Med. 2008. 36. (3). 683–689.
41. Liu Z.H., Wei R., Wu Y.P., Lisman T., Wang Z.X., Han J.J., Ren D.L., Chen B., Xia Z.L., Zhu Z., Zhang Y., Cui X., Hu H.T., de Groot P.G., Xu W.B. Elevated plasma tissue-type plasminogen activator (t-PA) and soluble thrombomodulin in patients suffering from severe acute respiratory syndrome (SARS) as a possible index for prognosis and treatment strategy // Biomed. Environ. Sci. 2005. 18. (4). 260–264.
42. Maroeska te Loo D., Bosma N., van Hinsbergh V., Span P., de Waal R., Clarijs R., Sweep C., Monnens L., van den Heuvel L. Elevated levels of vascular endothelial growth factor in serum of patients with D+ HUS // Pediatr. Nephrol. 2004. 19. (7). 754–760.
43. Martin F.A., Murphy R.P., Cummins P.M. Thrombomodulin and the vascular endothelium: insights into functional, regulatory, and therapeutic aspects // Am. J. Physiol. Heart Circ. Physiol. 2013. 304. (12). H1585–H1597.
44. Mok C.C., Poon W.L., Lai J.P.S., Wong C.K., Chiu S.M., Lun S.W.M., Ko G.T.C., Lam C.W.K., Lam C.S. Metabolic syndrome, endothelial injury, and subclinical atherosclerosis in patients with systemic lupus erythematosus // Scand. J. Rheumatol. 2010. 39. (1). 42–49.
45. Niitsu N., Okamoto M., Nakamine H., Yoshino T., Tamaru J.-I., Nakamura S., Higashihara M., Hirano M. Simultaneous elevation of the serum concentrations of vascular endothelial growth factor and interleukin-6 as independent predictors of prognosis in aggressive non-Hodgkin’s lymphoma // Eur. J. Haematol. 2002. 68. (2). 91–100.
46. Nilsen E.M., Johansen F.E., Jahnsen F.L., Lundin K.E.A., Scholz T., Brandtzaeg P., Haraldsen G. Cytokine profiles of cultured microvascular endothelial cells from the human intestine // Gut. 1998. 42. (5). 635–642.
47. Page A.V., Liles W.C. Biomarkers of endothelial activation/dysfunction in infectious diseases // Virulence. 2013. 4. (6). 507–516.
48. Pawlak K., Mysliwiec M., Pawlak D. Hepatitis C virus seropositivity and TNF superfamily receptors: sCD40, sFas – the new putative determinants of endothelial dysfunction in haemodialysis patients // Thromb. Res. 2010. 126. (5). 393–398.
49. Pedersen L.M., Jurgensen G.W., Johnsen H.E. Serum levels of inflammatory cytokines at diagnosis correlate to the bcl-6 and CD10 defined germinal centre (GC) phenotype and bcl-2 expression in patients with diffuse large B-cell lymphoma // Br. J. Haematol. 2005. 128. (6). 813–819.
50. Perez-Atayde A.R., Sallan S.E., Tedrow U., Connors S., Allred E., Folkman J. Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia // Am. J. Pathol. 1997. 150. (3). 815–821.
51. Righini M., Perrier A., de Moerloose P., Bounameaux H. D-Dimer for venous thromboembolism diagnosis: 20 years later // J. Thromb. Haemost. 2008. 6. (7). 1059–1071.
52. Riihijarvi S., Nurmi H., Holte H., Bjorkholm M., Fluge O., Pedersen L.M., Rydstrom K., Jerkeman M., Eriksson M., Leppa S. High serum vascular endothelial growth factor level is an adverse prognostic factor for high-risk diffuse large B-cell lymphoma patients treated with dose-dense chemoimmunotherapy // Eur. J. Haematol. 2012. 89. (5). 395–402.
53. Robinson C.J., Stringer S.E. The splice variants of vascular endothelial growth factor (VEGF) and their receptors // J. Cell Sci. 2001. 114. (Pt. 5). 853–865.
54. Rousseau A., Favier R., van Dreden P. Elevated circulating soluble thrombomodulin activity, tissue factor activity and circulating procoagulant phospholipids: New and useful markers for pre-eclampsia? // Eur. J. Obstet. Gynecol. Reprod. Biol. 2009. 146. (1). 46–49.
55. Roy L.D., Ghosh S., Pathangey L.B., Tinder T.L., Gruber H.E., Mukherjee P. Collagen induced arthritis increases secondary metastasis in MMTV-PyV MT mouse model of mammary cancer // BMC Cancer. 2011. 11. (1).
56. Sathupan P., Khongphattanayothin A., Srisai J., Srikaew K., Poovorawan Y. The role of vascular endothelial growth factor leading to vascular leakage in children with dengue virus infection // Ann. Trop. Paediatr. 2007. 27. (3). 179–184.
57. Shapiro N.I., Yano K., Okada H., Fischer C., Howell M., Spokes K.C., Ngo L., Angus D.C., Aird W.C. A prospective, observational study of soluble FLT-1 and vascular endothelial growth factor in sepsis // Shock. 2008. 29. (4). 452–457.
58. Taylan A., Sari I., Kozaci D.L., Yildiz Y., Bilge S., Coker I., Maltas S., Gunay N., Akkoc N. Evaluation of various endothelial biomarkers in ankylosing spondylitis // Clin. Rheumatol. 2011. 31. (1). 23–28.
59. Triggle C.R., Ding H. A review of endothelial dysfunction in diabetes: a focus on the contribution of a dysfunctional eNOS // J. Am. Soc. Hypertens. 2010. 4. (3). 102–115.
60. Urban M., Wojtkielewicz K., Glowinska B., Peczynska J. Soluble thrombomodulin – a molecular marker of endothelial cell injury in children and adolescents with obesity // Endokrynol. Diabetol. Chor. Przemiany Materii Wieku Rozw. 2005. 11. (2).73–77.
61. Walker T.S., Brown J.S., Hoover C.S., Morgan D.A. Endothelial Prostaglandin Secretion: Effects of Typhus Rickettsiae // J. Infect. Dis. 1990. 162. (5). 1136–1136.
62. Zhao W.-L., Mourah S., Mounier N., Leboeuf C., Daneshpouy M.E., Legres L., Meignin V., Oksenhendler E., Maignin C.L., Calvo F., Briere J., Gisselbrecht C., Janin A. Vascular endothelial growth factor-A is expressed both on lymphoma cells and endothelial cells in angioimmunoblastic T-cell lymphoma and related to lymphoma progression // Lab. Invest. 2004. 84. (11). 1512–1519.